Investment Thesis
FibroBiologics is a pre-revenue biotech company facing severe financial distress with accelerating losses (-67% YoY), negative operating cash flow of -$4.4M annually, and minimal cash runway (~4 months) given only $1.5M cash against $4.3M debt. The combination of zero revenue, deteriorating profitability, high leverage (1.65x debt/equity), and substantial cash burn with no visible capital deployment for R&D indicates imminent liquidity challenges without successful financing or commercialization.
Strengths
- Positive current ratio of 1.59x provides near-term liquidity cushion
- Minimal capex requirement ($0) reduces ongoing capital needs for operations
- Recent insider activity (8 Form 4 filings) may indicate management confidence in pipeline
Risks
- Critical cash runway of approximately 4 months at current burn rate creates imminent solvency risk
- No revenue generation with mounting operating losses suggests commercial failure or pre-launch stage with execution uncertainty
- High debt burden ($4.3M) relative to equity base ($2.6M) and cash position creates refinancing/restructuring risk
- Deteriorating financial metrics with net losses worsening 67% YoY indicates worsening operational trends
- Negative interest coverage (-1,267x) demonstrates inability to service debt from operations
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Revenue generation timeline and pipeline stage advancement
- Debt refinancing or capital raise activity
- Regulatory approval progress for lead candidates
- Changes in debt/equity ratio and balance sheet leverage
Financial Metrics
Revenue
N/A
Net Income
-5.0M
EPS (Diluted)
$-1.33
Free Cash Flow
-4.4M
Total Assets
5.9M
Cash
1.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-192.3%
ROA
-84.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.59x
Quick Ratio
1.59x
Debt/Equity
1.65x
Debt/Assets
56.2%
Interest Coverage
-1,267.00x
Long-term Debt
4.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:19:04.040571 |
Data as of: 2026-03-31 |
Powered by Claude AI